EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –

– Initiation of first Phase 3 clinical trial (LUGANO) of EYP-1901 in wet AMD expected in 2H 2024 –

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D. who has served as EyePoint’s Chief Medical Officer since 2016. Dr. Ribeiro is a trained retinal specialist and joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development.

“We are delighted to welcome Dr. Ribeiro to the EyePoint senior leadership team during an exciting time as we approach the anticipated Phase 2 PAVIA trial readout of EYP-1901 for NPDR in the second quarter and the initiation of our first Phase 3 LUGANO pivotal trial in wet AMD in the second half of this year,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “Ramiro is a proven leader with a strong scientific and clinical background, and a track record of successfully bringing novel therapies for patients. His wealth of experience will be an incredibly valuable addition to the team as we advance EYP-1901 and pipeline programs through clinical development and potential FDA approval. I also want to express my sincere gratitude to Dr. Paggiarino for his numerous contributions to EyePoint during his tenure. Dario’s clinical knowledge and leadership have been instrumental to our success.”

“I have devoted my career to bringing innovative treatments to patients suffering from sight-threatening conditions, and I believe that intravitreal sustained-delivery therapies using EyePoint’s Durasert E technology have great potential to transform the treatment paradigm for serious retinal diseases,” said Dr. Ribeiro. “EyePoint has built an impressive foundation as the leader in sustained intraocular drug delivery, demonstrated by the compelling efficacy and safety data of EYP-1901 observed in the Phase 1 DAVIO and Phase 2 DAVIO 2 trials. I am excited to work with the talented team at Eyepoint to drive the development of promising product candidates across Eyepoint’s portfolio and bring novel treatment options to patients around the world.”